EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Practical Guide to Optimal Adaptive Two‐Stage Designs for Various Endpoint Types

Nico Bruder iD, Jan Meis, Maximilian Pilz iD, Meinhard Kieser iD

Pharmaceutical Statistics · 2026

DOI: 10.1002/pst.70129 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2026. Verfasst von Nico Bruder und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany. Hauptthemen laut MEDLINE: Research Design, Endpoint Determination, Clinical Trials as Topic. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Health Initiative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adaptive designs are frequently used to adjust sample sizes based on interim data, ensuring reliable conclusions while protecting resources. To maximize trial efficiency, design parameters can be optimized to minimize an objective function (e.g., the expected sample size) while rigorously controlling overall error rates or further operating characteristics. However, existing methodological guidance for optimal adaptive designs mainly focuses on normally distributed data or discrete optimizations for binary data, leaving a limited practical framework to practitioners who work with other common endpoint types. We address this by demonstrating how the asymptotic normal approximations of standard test statistics enable the optimization framework to be systematically applied across diverse endpoint types, including binary and time‐to‐event data. Furthermore, we highlight critical pitfalls in using optimal adaptive designs for two‐sided testing. The results demonstrate that optimizing design parameters can substantially decrease expected sample sizes and improve conditional power compared to standard group‐sequential designs. Using this guidance, we aim to enable researchers to efficiently plan clinical trials in a broad spectrum of clinical settings, a factor that is especially crucial in rare disease research where only limited patient populations are available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignEndpoint DeterminationClinical Trials as TopicHumansSample SizeData Interpretation, StatisticalModels, Statistical

Stichwörter der Autor:innen

adaptive designclinical trialinterim analysisoptimal designsample size determinationstatistical hypothesis testing

Autor:innen und Institutionen

  • Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany.
  • Institute of Medical Statistics, Medical University of Vienna, Vienna, Austria.
  • Nürnberg School of Health, Ohm University of Applied Sciences Nuremberg, Nuremberg, Germany.

ORCID-Profile: Nico Bruder, Maximilian Pilz, Meinhard Kieser

Förderung

  • Innovative Health Initiative

Zitieren

APA

Bruder, N., Meis, J., Pilz, M., & Kieser, M. (2026). A Practical Guide to Optimal Adaptive Two‐Stage Designs for Various Endpoint Types. Pharmaceutical Statistics. https://doi.org/10.1002/pst.70129

Vancouver

Bruder N, Meis J, Pilz M, Kieser M. A Practical Guide to Optimal Adaptive Two‐Stage Designs for Various Endpoint Types. Pharmaceutical Statistics. 2026. doi:10.1002/pst.70129

BibTeX
@article{Bruder2026,
  author = {Bruder, Nico and Meis, Jan and Pilz, Maximilian and Kieser, Meinhard},
  title = {A Practical Guide to Optimal Adaptive Two‐Stage Designs for Various Endpoint Types},
  journal = {Pharmaceutical Statistics},
  year = {2026},
  doi = {10.1002/pst.70129}
}
Kostenlos starten →